Emerging treatments in cystic fibrosis

Drugs

Volumn 69, Issue 14, 2009, Pages 1903-1910

  Jones, Andrew M ^a   Helm, Jennifer M ^a  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AERUGEN; ALPHA 1 ANTITRYPSIN; AMIKACIN; ARIKACE; AZITHROMYCIN; AZTREONAM; BACTERIAL VACCINE; BRAMITOB; CIPROFLOXACIN; COBIPROSTONE; COLISTIN; COLOBREATHE; CORTICOSTEROID; DENUFOSOL; DOCOSAHEXAENOIC ACID; DORNASE ALFA; DURAMYCIN; FOSFOMYCIN; GLUTATHIONE; GS 9310 11; HE 3286; HYDROXYCHLOROQUINE; IBUPROFEN; ION TRANSPORT AFFECTING AGENT; LEUKOTRIENE B4 RECEPTOR ANTAGONIST; LEVOFLOXACIN; MANNITOL; MERIPASE; METHOTREXATE; MP 376; O POLYSACCHARIDE TOXIN A CONJUGATE VACCINE; PHOSPHODIESTERASE V INHIBITOR; PIOGLITAZONE; PLACEBO; SIMVASTATIN; SPI 8811; TOBRAMYCIN; TRIZYTEK; UNCLASSIFIED DRUG; UNINDEXED DRUG; VX 770; VX 809;

BONE DENSITY; CLINICAL EVALUATION; CLINICAL TRIAL; CYSTIC FIBROSIS; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; GENE THERAPY; HUMAN; LUNG DISEASE; MORBIDITY; MORTALITY; PHYSIOTHERAPY; PSEUDOMONAS AERUGINOSA; REVIEW; TREATMENT INDICATION;

ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS; CHLORIDE CHANNELS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; EXOCRINE PANCREATIC INSUFFICIENCY; EXPECTORANTS; GENE THERAPY; HUMANS; RESPIRATORY MUCOSA;

EID: 70349096824     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11318500-000000000-00000     Document Type: Review

References (59)

1. Boucher RC. New concepts of the pathogenesis of cystic fibrosis lung disease. Eur Respir J 2004; 23 (1): 146-158
2. Que C, Cullinan P, Geddes D. Improving rate of decline of FEV1 in young adults with cystic fibrosis. Thorax 2006; 61 (2): 155-157
3. Farrell PM, Lai HJ, Li Z, et al. Evidence on improved outcomes with early diagnosis of cystic fibrosis through neonatal screening: enough is enough! J Pediatr 2005; 147 (3 Suppl.): S30-6
4. Dodge JA, Lewis PA, Stanton M, et al. Cystic fibrosis mortality and survival in the UK: 1947-2003. Eur Respir J
5. Doring G, Meisner C, Stern M. A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients. Proc Natl Acad Sci U S A 2007; 104 (26): 11020-11025
6. Johansen HK, Gotzsche PC. Vaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosis. Cochrane Database Syst Rev 2008; (4): CD001399
7. Zuercher AW, Horn MP, Que JU, et al. Antibody responses induced by long-term vaccination with an octovalent conjugate Pseudomonas aeruginosa vaccine in children with cystic fibrosis. FEMS Immunol Med Microbiol 2006; 47 (2): 302-308
8. Doring G, Conway SP, Heijerman HG, et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 2000; 16 (4): 749-767
9. Lenoir G, Antypkin YG, Miano A, et al. Efficacy, safety, and local pharmacokinetics of highly concentrated neb-ulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Paediatr Drugs 2007; 9 Suppl. 1: 11-20
10. Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999; 340 (1): 23-30
11. Dupont LJ, Minic P, Fustik S, et al. A randomized placebo-controlled study of nebulized liposomal amikacin (Arikace ) in the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection [abstract]. 22nd Annual North American Cystic Fibrosis Conference; 2008 Oct 23-25; Orlando (FL)
12. McCoy KS, Quittner AL, Oermann CM, et al. Inhaled az-treonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med 2008; 178 (9): 921-928
13. Oermann CM, McCoy KS, Retsch-Bogart GZ, et al. Effect of multiple aztreonam lysine for inhalation cycles on disease-related endpoints and safety in patients with cystic fibrosis and Pseudomonas aeruginosa: interim analysis of 12 month data [abstract]. 31st European Cystic Fibrosis Conference; 2008 Jun 11-14; Prague
14. Geller DE, Flume P, Schwab R, et al. A phase 1 safety, tolerability and pharmacokinetic (PK) study of MP-376 (levofloxacin solution for inhalation) in stable cystic fibrosis patients [abstract]. 22nd Annual North American Cystic Fibrosis Conference; 2008 Oct 23-25; Orlando (FL)
15. Bruinenbeg P, Otulana B, Blanchard J, et al. The effect of once-a-day inhaled liposomal ciprofloxacin hydrochloride on sputum bacterial density in cystic fibrosis patients with chronic pulmonary P. aeruginosa colonization [abstract]. 22nd Annual North American Cystic Fibrosis Conference; 2008 Oct 23-25; Orlando (FL)
16. Stass H, Ludwig M, Nagelschmitz J, et al. Safety and phar-macokinetics of inhaled dry powder ciprofloxacin after single and multiple inhalations in patients with cystic fibrosis [abstract]. 22nd Annual North American Cystic Fibrosis Conference; 2008 Oct 23-25; Orlando (FL)
17. Wilson J, Moorehead L, Montgomery B. A phase 1 open label trial to assess the safety and tolerability of fosfomy-cin/tobramycin for inhalation (FTI) in subjects with cystic fibrosis or bronchiectasis [abstract]. 22nd Annual North American Cystic Fibrosis Conference; 2008 Oct 23-25; Orlando (FL)
18. Milla C, Chmiel J, McCoy KS, et al. A phase 1/2 randomized, double-blind, single dose, dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa [abstract]. 22nd Annual North American Cystic Fibrosis Conference; 2008 Oct 23-25; Orlando (FL)
19. Equi A, Balfour-Lynn IM, Bush A, et al. Long term azi-thromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 2002; 360 (9338): 978-984
20. Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003; 290 (13): 1749-1756
21. Wolter J, Seeney S, Bell S, et al. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 2002; 57 (3): 212-216
22. Lai HC, FitzSimmons SC, Allen DB, et al. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. N Engl J Med 2000; 342 (12): 851-859
23. Balfour-Lynn IM, Lees B, Hall P, et al. Multicenter randomized controlled trial of withdrawal of inhaled cortico-steroids in cystic fibrosis. Am J Respir Crit Care Med 2006; 173 (12): 1356-1362
24. Konstan MW, Schluchter MD, Xue W, et al. Clinical use of ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis. Am J Respir Crit Care Med 2007; 176 (11): 1084-1089
25. Lands LC, Milner R, Cantin AM, et al. High-dose ibuprofen in cystic fibrosis: Canadian safety and effectiveness trial. J Pediatr 2007; 151 (3): 249-254
26. Konstan MW, Hilliard KA, Bucur C, et al. Effect of proglitazone on sputum markers of inflammation in cystic fibrosis [abstract]. 22nd Annual North American Cystic Fibrosis Conference; 2008 Oct 23-25; Orlando (FL)
27. Martin SL, Downey D, Bilton D, et al. Safety and efficacy of recombinant alpha(1)-antitrypsin therapy in cystic fibrosis. Pediatr Pulmonol 2006; 41 (2): 177-183
28. Williams B, Robinette M, Slovis B, et al. Hydroxy-chloroquine-pilot study of anti-inflammatory effects in cystic fibrosis [abstract]. 22nd Annual North American Cystic Fibrosis Conference; 2008 Oct 23-25; Orlando (FL)
29. Konstan MW, Doring G, Lands LC, et al. Results of a phase II clinical trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of CF lung disease [abstract]. 19th North American Cystic Fibrosis Foundation Conference; 2005 Oct 15-17; Baltimore (MD)
30. Southern KW, Barker PM, Solis A. Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2004; (2): CD002203
31. Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis: the Pulmozyme Study Group. N Engl J Med 1994; 331 (10): 637-642
32. Hodson ME, McKenzie S, Harms HK, et al. Dornase alfa in the treatment of cystic fibrosis in Europe: a report from the Epidemiologic Registry of Cystic Fibrosis. Pediatr Pulmonol 2003; 36 (5): 427-432
33. Davies J, Trindade MT, Wallis C, et al. Retrospective review of the effects of rhDNase in children with cystic fibrosis. Pediatr Pulmonol 1997; 23 (4): 243-248
34. Nash EF, Stephenson A, Ratjen F, et al. Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis. Cochrane Database Syst Rev 2009; (1): CD007168
35. Donaldson SH, Bennett WD, Zeman KL, et al. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med 2006; 354 (3): 241-250
36. Elkins MR, Robinson M, Rose BR, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006; 354 (3): 229-240
37. Jaques A, Daviskas E, Turton JA, et al. Inhaled mannitol improves lung function in cystic fibrosis. Chest 2008; 133 (6): 1388-1396
38. Minasian C, Wallis C, Metcalfe C, et al. Bronchial provocation testing with dry powder mannitol in children with cystic fibrosis. Pediatr Pulmonol 2008; 43 (11): 1078-1084
39. Bilton D, Robinson P, Cooper P. Randomised, double blind, placebo-controlled study of Bronchitol (inhaled dry powder mannitol) in cystic fibrosis [abstract]. 32nd European Cystic Fibrosis Conference; 2009 Jun 10-13; Brest
40. Zeitlin PL, Boyle MP, Guggino WB, et al. A phase I trial of intranasal Moli1901 for cystic fibrosis. Chest 2004; 125 (1): 143-149
41. Grasemann H, Stehling F, Brunar H, et al. Inhalation of Moli1901 in patients with cystic fibrosis. Chest 2007; 131 (5): 1461-1466
42. Deterding RR, Lavange LM, Engels JM, et al. Phase 2 randomized safety and efficacy trial of nebulized denufosol tetrasodium in cystic fibrosis. Am J Respir Crit Care Med 2007; 176 (4): 362-369
43. Inspire Pharmaceuticals. Denufosol tetrasodium inhalation solution for cystic fibrosis: phase 3 press release; [online]. Available from URL: http://www.inspirepharm.com/ r-and-d/denufosol.php [Accessed 2009 Aug 10]
44. Gilead Sciences. Trial to assess the safety, tolerability and pharmacokinetics of GS-9411 in healthy male volunteers [ClinicalTrials.gov identifier NCT00800579]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2009 Aug 10]
45. Sucampo Pharmaceuticals Inc. Sucampo Pharmaceuticals initiates phase IIa safety and efficacy trial for proprietary agent SPI-8811 in treating cystic fibrosis [online]. Available from URL: http://www.sucampo.com/article-34.shtml [Accessed 2009 Aug 10]
46. Kerem E, Hirawat S, Armoni S, et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet 2008; 372 (9640): 719-727
47. Accurso FJ, Rowe SM, Durie PR, et al. Interim analysis of phase 2a study of VX-770 to evaluate safety, pharmaco-kinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D [abstract]. 22nd Annual North American Cystic Fibrosis Conference; 2008 Oct 23-25; Orlando (FL)
48. Alton EW, Stern M, Farley R, et al. Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial. Lancet 1999; 353 (9157): 947-954
49. Knowles MR, Hohneker KW, Zhou Z, et al. A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. N Engl J Med 1995; 333 (13): 823-831
50. Pringle IA, Hyde SC, Gill DR. Non-viral vectors in cystic fibrosis gene therapy: recent developments and future prospects. Expert Opin Biol Ther 2009; 9 (8): 991-1003
51. Lenoir G, Dubray C, Chiron R, et al. Recombinant gastric lipase for the treatment of fat malabsorption [abstract]. 22nd Annual North American Cystic Fibrosis Conference; 2008 Oct 23-25; Orlando (FL)
52. Borowitz D, Falzone RP, Fratazzi C. A phase 3 study of the efficacy and safety of ALTU-135 (Trizytek) for treatment of pancreatic insufficiency in CF [abstract]. 22nd Annual North American Cystic Fibrosis Conference; 2008 Oct 23-25; Orlando (FL)
53. Kerem E, Reisman J, Corey M, et al. Prediction of mortality in patients with cystic fibrosis. N Engl J Med 1992; 326 (18): 1187-1191
54. Gustafsson PM, De Jong PA, Tiddens HA, et al. Multiple-breath inert gas washout and spirometry versus structural lung disease in cystic fibrosis. Thorax 2008; 63 (2): 129-134
55. Lum S, Gustafsson P, Ljungberg H, et al. Early detection of cystic fibrosis lung disease: multiple-breath washout versus raised volume tests. Thorax 2007; 62 (4): 341-347
56. Brody AS, Tiddens HA, Castile RG, et al. Computed tomography in the evaluation of cystic fibrosis lung disease. Am J Respir Crit Care Med 2005; 172 (10): 1246-1252
57. Doring G, Elborn JS, Johannesson M, et al. Clinical trials in cystic fibrosis. J Cyst Fibros 2007; 6 (2): 85-99
58. Bartholdson SJ, Brown AR, Mewburn BR, et al. Plant host and sugar alcohol induced exopolysaccharide biosynthesis in the Burkholderia cepacia complex. Microbiology 2008; 154 (8): 2513-2521
59. Reid DW, Bell SC. Sugar sweet and deadly? Microbiology 2009; 155 (3): 665-666